The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

被引：0
|
作者：
Oflas, M. [1 ]
Simsek, D. Has [1 ]
Sanli, Y. [1 ]
Kuyumcu, S. [1 ]
Isik, E. [1 ]
Karadogan, S. [1 ]
Basaran, M. [2 ]
Ekenel, M. [2 ]
Mudun, A. [1 ]
Ozkan, Z. G. [1 ]
机构：
[1] Istanbul Fac Med, Dept Nucl Med, Istanbul, Turkiye
[2] Istanbul Univ, Dept Med Oncol, Inst Oncol, Istanbul, Turkiye
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0553
引用
收藏
页码：S649 / S650
页数：2
相关论文
共 50 条
  • [31] Comparison of 68Ga-PSMA and 177Lu-PSMA Total Metabolic Tumor Volume (TMTV) variations for monitoring metastatic castration-resistant prostate cancer in 177Lu-PSMA therapy.
    Boursier, C.
    Zaragori, T.
    Kunsch, J.
    Olivier, P.
    Claudin, M.
    Marie, P.
    Bros, M.
    Bordonne, M.
    Verger, A.
    Karcher, G.
    Imbert, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S361 - S362
  • [32] Evaluation of Nephrotoxicity of Extended Lu177-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer
    Topal, E.
    Kovan, B.
    Simsek, D. Has
    Civan, C.
    Sanli, M.
    Basaran, M.
    Sanli, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S151 - S152
  • [33] Factors predicting the early biochemical response to [177Lu]Lu-PSMA therapy in patients with metastatic castration resistant prostate cancer
    Al-Timimi, Ahmed
    Manafi-Farid, Reyhaneh
    Fallahi, Babak
    Beiki, Davood
    Askari, Emran
    Rezaei, Alireza
    Adinehpour, Zohreh
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2022, 30 (02): : 115 - 121
  • [34] SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617
    Demirci, Ridvan Arda
    Gulati, Roman
    Hawley, Jessica E.
    Yezefski, Todd
    Haffner, Michael C.
    Cheng, Heather H.
    Montgomery, Robert B.
    Schweizer, Michael T.
    Yu, Evan Y.
    Nelson, Peter S.
    Chen, Delphine L.
    Iravani, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1945 - 1951
  • [35] The correlation between PSMA PET/CT uptake and [177Lu]Lu-PSMA-I&T absorbed dose in Metastatic Castration-Resistant Prostate Cancer Patients.
    Kalloe, V.
    Owers, E. C.
    de Boer, M. M.
    Rijkhorst, E.
    Aalbersberg, E. A.
    Dotinga, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S424 - S424
  • [36] PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients
    Kleiburg, F.
    de Geus-Oei, L. F.
    Luelmo, S. A. C.
    Spijkerman, R.
    Goeman, J. J.
    Toonen, F. A. J.
    Smit, F.
    van der Hulle, T.
    Heijmen, L.
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 181
  • [37] Imaging of Metastatic Castration-Resistant Prostate Cancer - Comparison of 68Ga-RM2 and 68Ga-PSMA PET/CT
    Heuschkel, M.
    Kurth, J.
    Hakenberg, O. W.
    Schwarzenboeck, S. M.
    Krause, B. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S151 - S151
  • [38] Castration-Resistant Prostate Cancer Patterns of Metastasis Evaluated by 68Ga-PSMA PET/CT
    Silva, M.
    Silva, R.
    Lapa, P.
    Costa, G.
    Pedroso de Lima, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S721 - S721
  • [39] A comparison of 68Ga-PSMA PET/CT-based split renal function to 99mTc-MAG3 in patients with metastatic castration-resistant prostate carcinoma treated with 177Lu-PSMA
    Gabela, Lerato
    Harry, Lerwine
    Nxasana, Thembelihle
    Ndlovu, Nontobeko
    Mkhize, Thokozani
    Pillay, Venesen
    Masikane, Siphelele
    Patel, Maryam
    Hadebe, Bawinile
    Vorster, Mariza
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [40] PSA flare in patients with metastatic castration-resistant prostate cancer undergoing 177Lu-PSMA treatment.
    Li, Haoran
    Wulff-Burchfield, Elizabeth Marie
    Abbasi, Saqib
    Narang, Arshit
    Dal, Emre
    Donald, Joseph
    Yap, Wendell Y.
    Shen, Xinglei
    Chen, Ronald C.
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 157 - 157
12345